Kessler: FDA pre-emption is of no benefit to public

Share this article:
FDA pre-emption of “failure-to-warn” state lawsuits over drug risks does nothing to benefit the agency or the public and can prevent information that is helpful to the FDA, healthcare providers, and consumers from coming out, say commissioner David Kessler and Georgetown Law professor David Vladeck in the Georgetown Law Journal

While there has been a “steady stream” of such cases against drug companies brought by consumers injured by FDA-regulated drugs, the FDA has stayed on the sidelines, they report, and courts have decided them under the ordinary rules that govern state damages actions, with the question of preemption rarely, if ever, arising.

But Kessler and Vladeck say there are both legal and practical problems with the FDA's new position. They say the FDA's pro-pre-emption arguments are based on a reading of the Federal Food, Drug, and Cosmetic Act that, in their view, understates the ability of manufacturers to change labeling unilaterally to respond to newly discovered risks or to seek labeling changes from the FDA. 
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete October 2014 Digital Edition

Read the complete October 2014 Digital Edition

Click the above link to access the complete Digital Edition of the October 2014 issue of MM&M, with all text, charts and pictures.

Predicting your pink slip

Predicting your pink slip

Any time a firm needs to save money, high-salaried executives are targets